A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers

NCT05626803 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

Norovirus Infections

Interventions

DRUG: Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose
DRUG: Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose
DRUG: Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose
DRUG: Placebo

Sponsor

Vaxart